NZ536030A - HFA-suspension formulation of crystalline tiotropium bromide anhydrate - Google Patents

HFA-suspension formulation of crystalline tiotropium bromide anhydrate

Info

Publication number
NZ536030A
NZ536030A NZ536030A NZ53603003A NZ536030A NZ 536030 A NZ536030 A NZ 536030A NZ 536030 A NZ536030 A NZ 536030A NZ 53603003 A NZ53603003 A NZ 53603003A NZ 536030 A NZ536030 A NZ 536030A
Authority
NZ
New Zealand
Prior art keywords
hfa
tiotropium bromide
acid
suspension
suspension according
Prior art date
Application number
NZ536030A
Other languages
English (en)
Inventor
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NZ536030A publication Critical patent/NZ536030A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NZ536030A 2002-03-28 2003-03-20 HFA-suspension formulation of crystalline tiotropium bromide anhydrate NZ536030A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats
PCT/EP2003/002899 WO2003082244A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats

Publications (1)

Publication Number Publication Date
NZ536030A true NZ536030A (en) 2006-07-28

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ536030A NZ536030A (en) 2002-03-28 2003-03-20 HFA-suspension formulation of crystalline tiotropium bromide anhydrate

Country Status (21)

Country Link
EP (1) EP1492498A2 (no)
JP (1) JP5147158B2 (no)
KR (1) KR101005717B1 (no)
CN (1) CN1642525A (no)
AU (1) AU2003221509B2 (no)
BR (1) BR0308709A (no)
CA (1) CA2479638C (no)
DE (1) DE10214264A1 (no)
EA (1) EA008610B1 (no)
EC (1) ECSP045322A (no)
HR (1) HRP20040890A2 (no)
IL (1) IL163696A0 (no)
ME (1) ME00246B (no)
MX (1) MXPA04009338A (no)
NO (1) NO20044004L (no)
NZ (1) NZ536030A (no)
PL (1) PL371295A1 (no)
RS (1) RS52481B (no)
UA (1) UA79776C2 (no)
WO (1) WO2003082244A2 (no)
ZA (1) ZA200405637B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606549A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
KR20080007656A (ko) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 브로마이드의 신규한 결정질 형태
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
DK2435024T3 (en) * 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
MX2019003097A (es) * 2016-09-19 2019-09-13 Mexichem Fluor Sa De Cv Composicion farmaceutica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
EP1341538B1 (de) * 2000-10-31 2009-12-23 Boehringer Ingelheim Pharma GmbH & Co.KG Arzneimittelkompositionen aus tiotropiumsalzen und epinastin zur therapie von atemswegserkrankungen
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten

Also Published As

Publication number Publication date
KR20040098022A (ko) 2004-11-18
PL371295A1 (en) 2005-06-13
EA008610B1 (ru) 2007-06-29
KR101005717B1 (ko) 2011-01-05
DE10214264A1 (de) 2003-10-16
CN1642525A (zh) 2005-07-20
WO2003082244A3 (de) 2004-02-05
JP5147158B2 (ja) 2013-02-20
EP1492498A2 (de) 2005-01-05
EA200401159A1 (ru) 2005-04-28
ECSP045322A (es) 2005-01-28
CA2479638A1 (en) 2003-10-09
BR0308709A (pt) 2005-01-04
CA2479638C (en) 2011-01-04
WO2003082244A2 (de) 2003-10-09
YU86004A (sh) 2006-08-17
AU2003221509B2 (en) 2008-01-24
JP2005527550A (ja) 2005-09-15
UA79776C2 (en) 2007-07-25
HRP20040890A2 (en) 2005-06-30
ME00246B (me) 2011-05-10
IL163696A0 (en) 2005-12-18
NO20044004L (no) 2004-10-05
MXPA04009338A (es) 2005-01-25
RS52481B (en) 2013-02-28
MEP47308A (en) 2011-02-10
AU2003221509A1 (en) 2003-10-13
ZA200405637B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
US7736627B2 (en) HFA suspension formulations containing an anticholinergic
CA2450961C (en) Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US20030171586A1 (en) Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US20030087927A1 (en) Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
MXPA03003221A (es) Monohidrato cristalino, procedmiento para su preparacion y su uso para la preparacion de un medicamento.
AU2004285684B2 (en) Novel crystalline anhydride with anticholinergic effect
ZA200602342B (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
WO2004054580A1 (en) Tiotropium containing hfc solution formulations
EP1682543B1 (de) Verfahren zur herstellung neuer tiotropiumsalze
CA2479638C (en) Hfa-suspension formulations of crystalline tiotropium bromide anhydrate
CA2479640C (en) Hfa suspension formulations containing an anticholinergic
US7244415B2 (en) HFA suspension formulations of an anhydrate

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 MAR 2016 BY DENNEMEYER SA

Effective date: 20130208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2017 BY DENNEMEYER + CO

Effective date: 20160222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2018 BY DENNEMEYER + CO.

Effective date: 20170217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2019 BY DENNEMEYER + CO

Effective date: 20180220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2020 BY DENNEMEYER

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2021 BY DENNEMEYER + CO.

Effective date: 20200219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2022 BY DENNEMEYER + CO.

Effective date: 20210308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAR 2023 BY PETRA OLK

Effective date: 20220307

EXPY Patent expired